Reuters logo
J&J declares Actelion tender offer a success, sees closing in second quarter
March 31, 2017 / 5:23 AM / 8 months ago

J&J declares Actelion tender offer a success, sees closing in second quarter

ZURICH (Reuters) - Johnson & Johnson (JNJ.N) declared its $30 billion tender offer for Swiss biotechnology company Actelion ATLN.S successful on Friday, reporting it controlled 77.2 percent of the voting rights after the main offer period.

FILE PHOTO:Bottles of Johnson's baby oil, made by Johnson & Johnson, are seen on a supermarket shelf in Seattle, Washington, U.S., February 10, 2017. REUTERS/Chris Helgren

The price of the offer, which J&J announced on Jan. 26, was $280 per share for Actelion. It said it expected the transaction to close in the second quarter.

J&J has said it intends to delist Actelion, while a new research and development company being spun out of Actelion, to be called Idorsia and led by Actelion founder Jean-Paul Clozel, will have a separate Swiss listing.

Reporting by Michael Shields; editing by Brenna Hughes Neghaiwi

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below